HomeAbout IOFPatients & PublicHealth ProfessionalsPolicy & AdvocacyNewsroomIOF Members Only  
Print this page Recommend this page

Strontium Ranelate

Two large phase III trials have shown that a daily oral dose of 2 g of strontium ranelate reduces the risk of vertebral fractures by 40-50%, and also reduces the risk of nonvertebral fractures (1). Hip fracture risk was decreased by 36% in elderly women with osteoporosis (2). Strontium ranelate increases BMD markedly. Its mechanism of action is not fully understood, but appears to involve a dual effect with a mild reduction of bone resorption and a maintenance or mild increase of bone formation.

References

  1. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector T, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-68.
  2. Reginster JY, Seeman MC, De Vernejoul S, Adami J, Compston O, Phenekos JP, Devogelaer M, Diaz Curiel A, Sawicki S, Goemaere OH, Sorensen D, Felsenberg D, Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816-22.
top